Home › Cases › Before the Chemotherapy
Tumour Lysis Syndrome
Before the Chemotherapy
6 questions
Question 1 · Who Is At Risk
Correct answer: Burkitt's lymphoma, or ALL/AML with a WBC above 100 × 10⁹/L, or CLL starting venetoclax with a lymph node ≥10cm
Why
TLS risk depends on disease stage/burden, treatment and patient factors.
- High: advanced Burkitt/lymphoblastic lymphoma, or early disease with LDH ≥2× ULN or bulk; AML WBC ≥100×10⁹/L; ALL WBC ≥100×10⁹/L and/or bulk
- Other high-grade lymphoma: early normal-LDH/non-bulky disease is low; early raised-LDH/bulky or advanced normal-LDH/non-bulky disease is intermediate; advanced disease with LDH ≥2× ULN or bulk is high
- AML/ALL below 100 without high-risk modifiers and early non-bulky Burkitt with LDH <2× ULN are intermediate. Low-grade lymphoma, CLL on BTK inhibitors/alkylating therapy, conventional-treatment myeloma and most solid tumours are generally low; renal dysfunction, spontaneous TLS or novel therapies can increase risk
- Venetoclax is worth remembering specifically — CLL risk ranges low to high, depending on tumour burden and patient factors. Any lymph node ≥10cm, or a node ≥5cm with ALC ≥25×10⁹/L, is high tumour burden; reduced renal function (CrCl <80ml/min) adds risk. The dose ramp-up, prophylaxis and blood monitoring are essential even in lower-risk patients
- The risk drives the prophylaxis, so it is assessed before chemotherapy
Key point
Burkitt's, high WBC leukaemias, and venetoclax. Venetoclax-treated CLL risk ranges low to high: assess node size, ALC and renal function; retain ramp-up, prophylaxis and monitoring.
Question 2 · Prevention
Correct answer: 2–3 L/day total oral/IV fluid, starting the day before treatment; consider IV hydration for high risk or inadequate oral intake, with fluid-balance monitoring
Why
Adult prevention: 2–3 L/day total oral/IV fluid, starting the day before treatment. Consider IV hydration, such as 0.9% sodium chloride, for high-risk patients or if oral intake is inadequate.
- Review renal function, urine output and fluid balance; adjust for cardiac/renal impairment
- Avoid potassium and phosphate in IV fluids — both are released in TLS
- Do NOT alkalinise with bicarbonate — it worsens calcium phosphate precipitation
- Prevention starts before chemotherapy; oral intake can contribute to the target
- Established TLS is different: initially 3 L/m²/day IV, aiming for urine output 100 mL/m²/hr, adjusted to renal function and clinical/fluid status
Key point
Adult prevention: 2–3 L/day total oral/IV, starting before treatment. Consider IV hydration if high risk or unable to drink enough; monitor fluid balance. No potassium/phosphate in IV fluids; no bicarbonate.
Question 3 · Allopurinol
Correct answer: It reduces de novo uric acid synthesis but does not degrade uric acid already present — so it is not adequate alone for high-risk patients
Why
Allopurinol 300mg OD PO, starting 24 to 48 hours before chemotherapy. It reduces de novo uric acid synthesis but does not degrade pre-existing uric acid — and it is not adequate alone for high-risk patients.
- That is exactly why rasburicase exists: it degrades uric acid rather than preventing its formation
- Reduce dose in renal impairment (e.g. 100mg OD); severe impairment may need <100mg/day or 100mg at longer intervals — confirm with haematology/pharmacy.
- It is appropriate prophylaxis for low and intermediate risk
- Remember it interacts significantly with azathioprine
Key point
Allopurinol prevents new uric acid; rasburicase destroys existing uric acid. Different jobs.
Question 4 · The Contraindication
Correct answer: G6PD status — rasburicase is contraindicated in G6PD deficiency and causes haemolytic anaemia
Why
Rasburicase is CONTRAINDICATED in G6PD deficiency — it causes haemolytic anaemia. Check G6PD status before prescribing.
- Rasburicase converts uric acid to allantoin, generating hydrogen peroxide, which a G6PD-deficient red cell cannot handle
- HLA-B*58:01 is checked before allopurinol in at-risk ethnicities, for severe cutaneous reactions — a different drug and a different test
- TPMT is checked before azathioprine
- Three drugs, three genetic checks, and they are easy to confuse
Key point
G6PD before rasburicase; HLA-B*58:01 before allopurinol; TPMT before azathioprine.
Question 5 · A Sampling Trap
Correct answer: It must be kept on ice — rasburicase continues to degrade uric acid ex vivo at room temperature, giving a falsely low result
Why
Uric acid samples must be kept on ice — rasburicase degrades uric acid ex vivo at room temperature.
- A sample left at room temperature returns a falsely reassuring low uric acid, and someone may then conclude the TLS is controlled when it is not
- This is an unusual and genuinely important pre-analytical trap, and the laboratory will not necessarily catch it
- Tell the person taking the sample, not just the form
- Light protection is relevant to other assays, not this one
Key point
Uric acid on ice after rasburicase. Otherwise the enzyme keeps working in the bottle.
Question 6 · The Definition
Correct answer: Lab TLS: two or more of uric acid ≥476, K⁺ ≥6, phosphate ≥1.45, Ca²⁺ ≤1.75. Clinical TLS: lab TLS plus creatinine ≥1.5× ULN, arrhythmia or seizure
Why
Adult Cairo-Bishop laboratory TLS: ≥2 different metabolic abnormalities within 3 days before to 7 days after treatment. Each parameter qualifies by its threshold or baseline change: urate ≥476 μmol/L or ≥25% rise; K+ ≥6 mmol/L or ≥25% rise; phosphate ≥1.45 mmol/L or ≥25% rise; calcium ≤1.75 mmol/L or ≥25% fall.
- Clinical TLS is laboratory TLS plus creatinine ≥1.5× ULN, arrhythmia or seizure
- The pattern makes mechanistic sense: cells release potassium, phosphate and nucleic acids (which become uric acid), and the phosphate binds calcium, driving it down
- A raised LDH marks tumour burden and risk, but is not a Cairo-Bishop criterion
- A single abnormality is not TLS
Key point
Two of four for lab TLS; add an organ event for clinical TLS. Potassium, phosphate, urate up; calcium down.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.